Interestingly, while as in the GEMM tumours FBXW7 mutation was associated with enrichment of MYC signalling in the human endometrial cancers, this was not the case in the colon cancer cells, and dysregulation of p53 gene sets was less evident in both, possibly owing to different p53 targets in mouse and human, or mutations in TP53 and other genes in its pathway in the human samples (Fig 3A–C). This evidence concerns the gene TP53 and endometrial cancer.